Press Releases

  • VolitionRx Announces Engagement of MissionIR Investor Relations Services

  • VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps

  • VolitionRx to Present at the 6th Annual LD Micro Conference

  • VolitionRx Expands Sample Size to 11,000 in Pivotal Colorectal Cancer Trial with Hvidovre Hospital, Denmark

  • First VolitionRx Study Data Presented at CNAPS, Baltimore

  • VolitionRx and Active Motif enter into Distribution Agreement for Volition's Research Use Only ELISA Kits

  • VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant

  • VolitionRx to use Innova Biosciences' Biotin Technology in its Epigenetic Research Kits

  • VolitionRx Embarks on Colorectal Cancer Trial with Hvidovre Hospital, Denmark

  • Racepoint Group Appointed by VolitionRx to Raise Awareness of its new Early-Stage Cancer Diagnostic

arrow-down arrow-left arrow-right arrow chevron-down circle-link--red circle-link close play plus